Penetrating Aortic Ulcer

4

Review clinical trials related to Penetrating Aortic Ulcer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies

This is a single-center study to evaluate the safety and effectiveness of three investigational devices, the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and the Surgeon-Modified Endografts in the treatment of Juxtarenal, Suprarenal, Thoracoabdominal, and Aortic Arch pathologies involving the at least one brachiocephalic artery or visceral vessels. The three investigational devices offer an endovascular approach to treat complex aortic pathologies that cannot be treated with commercially available devices. This customized, endovascular approach has the potential to decrease hospital length of stay, pulmonary complications, and in-hospital mortality.

Participants needed: 410
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of Alabama at BirminghamUpdated: Jan 6, 2026Locations: 1
Eligibility criteria

Intact or contained ruptured aortic or aortoiliac aneurysms (atherosclerotic/deg... [+40]

Less than 18 years of age [+28]

Status: Recruiting

NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.

Participants needed: 110
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Endospan Ltd.Updated: Oct 20, 2025Locations: 32
Eligibility criteria

Male and female age ≥ 18. [+30]

Acute dissection [+30]

Status: Recruiting

Concave Supra-arch Branched Stent-Graft System for Endovascular Treatment of Aortic Arch Diseases

The objective of the study is to evaluate the safety and efficacy of the Lifetech Concave Supra-arch Branched Stent-Graft System for Endovascular Treatment of Aortic Arch Diseases

Participants needed: 103
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Lifetech Scientific (Shenzhen) Co., Ltd.Updated: Jul 28, 2025Locations: 17
Eligibility criteria

Patients who are aged 18 to 80 years inclusive; [+8]

Patients either with ruptured or infected aneurysms; [+19]

Status: Recruiting

CRATOS - Evaluation of Cratos™ Branch Stent Graft System in Treatment of Descending Aorta Lesions

The goal of this prospective, interventional, multicentre, single-arm performance objective study is to evaluate efficacy and safety of Cratos™ Branch Stent Graft System in treatment of lesions (dissection, IMH and PAU in descending aorta. The main question\[s\] it aims to answer are: * 30-day all-cause Mortality rate * Composite of the following events from the time of enrolment through 12-month: * Device Technical Success * Absence of: Aortic rupture, Lesion-related mortality, Disabling Stroke, Permanent paraplegia, Permanent paraparesis, New onset renal failure requiring permanent dialysis, Additional unanticipated post-procedural surgical or interventional procedure related to the device, procedure, or withdrawal of the device system Participants will come for hospital office visits 1, 6, 12, 24-, 36-, 48- and 60-months post-procedure for the following, but not limited to assessments: * Physical examination * Modified Rankin scale * Tarlov scoring scale * CTA

Participants needed: 130
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai MicroPort Endovascular MedTech(Group)Co., LtdUpdated: Feb 26, 2025Locations: 1
Eligibility criteria

Presence of thoracic aortic pathology (Dissection, including IMH and ULP; and PA... [+14]

Concomitant disease of the ascending aorta or aneurysm of the abdominal aorta re... [+20]